- Home
- IMPP vs MGNX Comparison
IMPP vs MGNX Comparison
Compare IMPP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- MGNX
- Stock Information
- Founded
- IMPP 1981
- MGNX 2000
- Country
- IMPP Greece
- MGNX United States
- Employees
- IMPP N/A
- MGNX N/A
- Industry
- IMPP Marine Transportation
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- IMPP Consumer Discretionary
- MGNX Health Care
- Exchange
- IMPP Nasdaq
- MGNX Nasdaq
- Market Cap
- IMPP 88.4M
- MGNX 97.2M
- IPO Year
- IMPP N/A
- MGNX 2013
- Fundamental
- Price
- IMPP $2.78
- MGNX $1.51
- Analyst Decision
- IMPP
- MGNX Hold
- Analyst Count
- IMPP 0
- MGNX 9
- Target Price
- IMPP N/A
- MGNX $5.33
- AVG Volume (30 Days)
- IMPP 118.0K
- MGNX 398.0K
- Earning Date
- IMPP 05-23-2025
- MGNX 05-13-2025
- Dividend Yield
- IMPP N/A
- MGNX N/A
- EPS Growth
- IMPP N/A
- MGNX N/A
- EPS
- IMPP 1.40
- MGNX N/A
- Revenue
- IMPP $147,479,980.00
- MGNX $154,050,000.00
- Revenue This Year
- IMPP $3.05
- MGNX N/A
- Revenue Next Year
- IMPP $47.92
- MGNX $45.52
- P/E Ratio
- IMPP $1.98
- MGNX N/A
- Revenue Growth
- IMPP N/A
- MGNX 255.31
- 52 Week Low
- IMPP $2.12
- MGNX $0.99
- 52 Week High
- IMPP $4.59
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- IMPP 63.52
- MGNX 47.02
- Support Level
- IMPP $2.45
- MGNX $1.44
- Resistance Level
- IMPP $2.81
- MGNX $1.59
- Average True Range (ATR)
- IMPP 0.13
- MGNX 0.12
- MACD
- IMPP -0.00
- MGNX 0.00
- Stochastic Oscillator
- IMPP 67.35
- MGNX 40.91
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.